Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Early Phase 1 Interventional Results available

Biomarker Study in Participants With Migraine

ClinicalTrials.gov ID: NCT02766517

Public ClinicalTrials.gov record NCT02766517. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

LY2951742 Biomarker Study in Patients With Migraine

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo. This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993. The study will last about five days.

Study identification

NCT ID
NCT02766517
Recruitment status
Completed
Study type
Interventional
Phase
Early Phase 1
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
37 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 27, 2016
Primary completion
Dec 31, 2016
Completion
Dec 31, 2016
Last update posted
Apr 8, 2019

2016 – 2017

United States locations

U.S. sites
14
U.S. states
7
U.S. cities
12
Facility City State ZIP Site status
Arizona Research Center Phoenix Arizona 85023
Pharmacology Research Institute, Newport Beach Encino California 91316
Parexel Early Phase Unit at Glendale Glendale California 91206-4140
Pharmacology Research Institute, Newport Beach Los Alamitos California 90720
Pharmacology Research Institute, Newport Beach Newport Beach California 92660
Medical Center for Clinical Research San Diego California 92108
California Clinical Trials San Diego California 92123
Avail Clinical Research LLC DeLand Florida 32720
Psychiatric Inst of Florida-Clinical Neuroscience Solutions Orlando Florida 32801
PharmaSite Research Inc Baltimore Maryland 21208
PAREXEL-Phase 1 Baltimore Harbor Hospital Center Baltimore Maryland 21225
Rochester Clinical Research, Inc. Rochester New York 14609
CNS Health Care Memphis Tennessee 38119
Northwest Clinical Research Center Bellevue Washington 98007-4209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02766517, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 8, 2019 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02766517 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →